Abstract
Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases. In multiple sclerosis, available evidence suggests that oral azathioprine reduces relapse rates, provides a slight benefit on disability, and reduces new inflammatory lesions. Here, we focus on molecular mechanisms of Azathioprine and on its usefulness in multiple sclerosis.
Keywords: Azathioprine, multiple sclerosis, immunosuppression, thiopurine methyltransferase, tolerability, relapses, disability, immunomodulators
Mini-Reviews in Medicinal Chemistry
Title: Azathioprine in Multiple Sclerosis
Volume: 8 Issue: 9
Author(s): Paolo Invernizz, Maria Donata Benedetti, Sarah Poli and Salvatore Monaco
Affiliation:
Keywords: Azathioprine, multiple sclerosis, immunosuppression, thiopurine methyltransferase, tolerability, relapses, disability, immunomodulators
Abstract: Azathioprine is an immunosuppressive and steroid-sparing purine analogue, used in the treatment of several autoimmune diseases. In multiple sclerosis, available evidence suggests that oral azathioprine reduces relapse rates, provides a slight benefit on disability, and reduces new inflammatory lesions. Here, we focus on molecular mechanisms of Azathioprine and on its usefulness in multiple sclerosis.
Export Options
About this article
Cite this article as:
Invernizz Paolo, Benedetti Donata Maria, Poli Sarah and Monaco Salvatore, Azathioprine in Multiple Sclerosis, Mini-Reviews in Medicinal Chemistry 2008; 8 (9) . https://dx.doi.org/10.2174/138955708785132756
DOI https://dx.doi.org/10.2174/138955708785132756 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy The Long and Winding Road: Searching for Non-MHC Psoriasis Susceptibility Loci
Current Genomics Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Influence of Genetic Polymorphisms on Mycophenolic Acid Pharmacokinetics and Patient Outcomes in Renal Transplantation
Current Drug Metabolism Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets